Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.64
-0.02 (-0.16%)
Jul 17, 2026, 9:44 AM EDT - Market open
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,186,421
Market Cap
434.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 19 | 3 | 18.75% |
| Jun 30, 2024 | 16 | -2 | -11.11% |
| Jun 30, 2023 | 18 | 0 | - |
| Jun 30, 2022 | 18 | 4 | 28.57% |
| Jun 30, 2021 | 14 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| Cabaletta Bio | 158 |
| Sutro Biopharma | 133 |
| Kyverna Therapeutics | 129 |
| Artiva Biotherapeutics | 106 |
| Editas Medicine | 87 |
| Prelude Therapeutics | 79 |
| Prothena Corporation | 67 |
BNTC News
- 5 weeks ago - Guggenheim downgrades Benitec to Neutral, terminates coverage - TheFly
- 5 weeks ago - Benitec Biopharma downgraded to Neutral from Buy at Guggenheim - TheFly
- 2 months ago - Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 months ago - Benitec Biopharma Earnings release: Q3 2026 - Filings
- 2 months ago - Benitec Biopharma Quarterly report: Q3 2026 - Filings
- 2 months ago - Benitec Biopharma initiated with an Outperform at Evercore ISI - TheFly
- 2 months ago - Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 4 months ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire